Physicians' Academy for Cardiovascular Education

SGLT2 inhibitor reduces adverse outcomes across the spectrum of heart failureHF risk in diabetics

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial

Literature - Fitchett D, Butler J, van de Borne P, et al. - Eur Heart J 2018;39:363–370

Main results

Conclusion

A sub-analysis of the EMPA-REG OUTCOME study showed that empagliflozin provides clinical benefit for diabetic patients with or without HF, and to those at high and low HF risk. This benefit occurred after 12 weeks of therapy and persisted throughout the study.

Editorial comment

In his editorial article, Paneni [6] provides insights into the pathophysiology of early benefit of empagliflozin, which include its effects on glycemic control, osmotic diuresis and blood pressure, as well as the inhibition of the sodium-hydrogen exchange and the slower progression of kidney disease. He also notes the study limitations including that HF hospitalizations were not centrally adjudicated, the lack of specific cardiac measures like the ejection fraction, the possible underestimation of HF prevalence and incidence, and the low number of events in the HF risk subgroups.

The author concludes: ‘Overall, the present study provides novel insights to believe that empagliflozin, and perhaps other SGLTL-2 inhibitors, may act across the spectrum of diabetic heart disease, from early stages of diabetic cardiomyopathy to congestive HF.’ (…)‘This ‘”self-limiting’ limiting” action of SGLT-2 inhibitors may suggest their use also in patients without diabetes (i.e. pre-diabetes, obesity, hypertension) to prevent adverse cardiac remodelling and dysfunction. Future studies will help us to characterize further and appreciate the potential of empagliflozin and other SGLT-2 inhibitors to fight the epidemic of HF.’

References

Show references

Download the slide

Share this page with your colleagues and friends: